Trillium Therapeutics Inc.

87 articles about Trillium Therapeutics Inc.

• Trillium Therapeutics Announces Changes to Its Board of Directors

  2/7/2020

  Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020. 

• Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

  1/29/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 41,279,090 common shares of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares of the Company (the “Offering”

• Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

  1/23/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 35,731,818 common shares (the “Common Shares”) of the Company and 1,250,000 Series II Non-Voting Convertible First Preferred Shares (the “Series II First Preferred Shares”) of the Company (the “Offering”).

• Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

  1/22/2020

  Trillium Therapeutics Inc. announced that it has commenced a public offering of common shares of the Company and Series II Non-Voting Convertible First Preferred Shares of the Company.

• Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

  1/16/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the Company has regained compliance with the Nasdaq Capital Market minimum bid price requirement, and the matter is now closed.

• Biotechnological Breakthroughs Help Revamp the Fight Against Cancer

  1/9/2020

  Biotechnology plays an important role throughout various sectors by improving industry standards, services, and developing new products.

• Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

  1/7/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on its TTI-621 and TTI-622 clinical programs.

• Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  11/14/2019

  Trillium Therapeutics Inc. reported financial results for the nine months ended September 30, 2019, and provided a corporate update.

• Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting

  11/6/2019

  Trillium Therapeutics Inc. announced that new preclinical data from its STING agonist program will be presented at the 34th annual meeting of the Society for Immunotherapy of Cancer The meeting will be held November 6-10 in National Harbor, MD. The poster presentation will highlight the anti-tumor activity of TTI-10001, a novel small molecule STING agonist, when delivered intravenously or orally.

• Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update

  10/22/2019

  Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate restructuring to extend the company’s cash runway and to focus on critical value-creating activities

• 

  BioSpace Movers and Shakers for Week of June 4th

  6/11/2018

  Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.

• Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

  2/9/2018

  Trillium announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences.

• Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

  1/17/2018

  The company also announced that Eric Sievers, MD, has transitioned from Chief Medical Officer to Senior Clinical Advisor.

• Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

  12/12/2017

  Trillium Therapeutics announced today that new clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the American Society of Hematology 59th Annual Meeting, December 9-12, in Atlanta.

• Trillium Announces Closing of Private Placement

  12/4/2017

  Trillium announced the closing of its non-brokered private placement, previously announced on November 15, 2017, of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share for gross proceeds of U.S.$19,975,000.

• Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

  11/20/2017

  TTI-2341 had potent activity against a broad range of EGFR variants, including disease-relevant mutants T790M and C797S.

• Trillium Announces Private Placement

  11/16/2017

  Trillium today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U.S.$19,975,000.

• Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

  11/10/2017

  As of September 30, 2017, Trillium had cash and marketable securities of $64.3 million compared to $50.5 million at December 31, 2016.

• Trillium Therapeutics to Present at Upcoming Scientific Conferences

  11/7/2017

  announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming scientific conferences: Society for Immunotherapy of Cancer 32nd Annual Meeting, Society for Neuro Oncology 22nd Annual Meeting and American Society of Hematology 59th Annual Meeting.

• Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

  10/18/2017

  Trillium Therapeutics announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England.